ADVFN US – Market Content Editor
-
InTest posts third profitable quarter in a row
Demonstrating sustained operational momentum, InTest Corporation (NYSEAM: INTT) closed Q2 2026 in positive financial territory—marking its third consecutive quarter of profitability. Driven primarily by robust demand across the automotive and industrial sectors, the global testing and process technology supplier generated US$35.3 million in revenue, representing a US$1.4 million sequential increase over Q1 and a US$7.2…
-
American Fusion Appoints John Gerdin as Independent Director to Strengthen Capital Markets Strategy
John Gerdin joins American Fusion’s board and advisory team with experience in international finance and capital formation as the company advances its developmental Texatron Fusion Engine and builds its corporate infrastructure. Key Investor Takeaways Why AMFN Stock Is in Focus American Fusion (USOTC:AMFN) appointed John Gerdin to its Board of Directors as an Independent Director…
-
Premier Graphene Posts First Profitable Quarter and Targets Further Profit Growth
Premier Graphene reported its first profitable quarter in company history following the completion of commercial contracts, while management said it expects profitability to increase in the third quarter. Key Investor Takeaways Why BIEI Stock Is in Focus Premier Graphene (USOTC:BIEI) reported its first profitable quarter in corporate history, with management saying completed contracts generated sufficient…
-
La Rosa Holdings Launches Strategic Alternatives Review and Ends Consensus Core Technologies Deal
La Rosa Holdings is evaluating transactions, acquisitions, partnerships and asset divestitures after terminating its proposed Consensus Core Technologies transaction, while separately regaining compliance with Nasdaq’s periodic filing requirement. Key Investor Takeaways Why LRHC Stock Is in Focus La Rosa Holdings (NASDAQ:LRHC) has begun a comprehensive strategic alternatives review aimed at strengthening its operating platform and…
-
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
Heron Therapeutics reported modest second-quarter revenue growth, but uncertainty around potential generic CINVANTI competition and a strategic alternatives process prompted the company to withdraw its full-year 2026 guidance. Key Investor Takeaways Why HRTX Stock Is in Focus Heron Therapeutics (NASDAQ:HRTX) withdrew its full-year 2026 guidance after second-quarter revenue came in below internal expectations and uncertainty…
-
Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even
Quanterix reported 34% second-quarter revenue growth and lower adjusted cash usage, but weaker-than-expected commercial performance prompted a substantial guidance reduction and pushed expected cash-flow break-even into 2027. Key Investor Takeaways Why QTRX Stock Is in Focus Quanterix (NASDAQ:QTRX) lowered its 2026 financial outlook after second-quarter revenue failed to meet management’s expectations despite increasing 34% year…
-
Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103
The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom endpoint, although prespecified subgroup and biomarker findings are prompting Tenax to pursue a revised registrational strategy with the FDA. Key Investor Takeaways Why TENX Stock Is in Focus Tenax Therapeutics (NASDAQ:TENX) reported that its 241-patient Phase 3…
-
5E Advanced Materials Secures $8 Million EXIM Investment for Fort Cady Boron Project
The federal investment supports development of Fort Cady and precedes 5E Advanced Materials’ application for a potential $285 million project debt facility as the project moves toward a Final Investment Decision. Key Investor Takeaways Why FEAM Stock Is in Focus 5E Advanced Materials (NASDAQ:FEAM) has secured an $8 million EXIM investment for its Fort Cady…
-
Varex Q3 FY2026 Results Show Revenue Growth and Margin Expansion Ahead of Teledyne Transaction
Varex Imaging reported higher revenue, stronger non-GAAP margins and improved earnings, although tariff refunds and related customer reimbursements provided a roughly $10 million benefit to quarterly gross profit. Key Investor Takeaways Why VREX Stock Is in Focus Varex Imaging (NASDAQ:VREX) reported Q3 FY2026 revenue growth alongside substantial improvement in margins and earnings, supported by continued…
-
Bowman Reports Q2 2026 Revenue Growth as Backlog Jumps 50% Ahead of $43-Per-Share Acquisition
Bowman Consulting Group delivered double-digit second-quarter growth and reaffirmed its 2026 guidance, while a separate agreement to be acquired by Bernhard Capital Partners shifts investor attention toward the pending all-cash transaction. Key Investor Takeaways Why BWMN Stock Is in Focus Bowman Consulting Group (NASDAQ:BWMN) reported strong Q2 2026 revenue growth and a sharply higher backlog…